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A B S T R A C T
Perforin is an important mediator of inflammatory reactions. It is a quick-action cytotoxic mediator accumulated in
the cytoplasmic granules of effector immunity cells (T lymphocytes, NK and NKT cells) which provide death signal in in-
fected or transformed cells. Perforin-positive cells were previously detected in myocardial tissue during Trypanosoma
cruzi infection and viral myocarditis while its role in chronic and progressive cardiovascular inflammatory disease such
as atherosclerosis is almost completely unexplored. The perforin activity is also untested during acute coronary events
that represent unexpected atherosclerotic complications due to the inflammatory destabilisation and atherosclerotic plaque
rupture. The aim of this study was to investigate the presence of perforin, an important immunological inflammatory
molecule in peripheral blood lymphocytes during the early period after acute myocardial infarction. We analyzed three
subject groups: women with ST-segment elevation acute myocardial infarction (STEMI) treated with primary percuta-
neous coronary intervention (PCI), conservatively treated women with acute myocardial infarction without ST-segment
elevation (NSTEMI) and a control group of healthy volunteers. The STEMI and NSTEMI groups did not basically differ
in medication neither in levels of routine laboratory tests, while troponin I were significantly higher in the STEMI
group. In the study, we detected an early decrease of perforin-positive lymphocytes in STEMI patients that were in con-
trast with their persisting elevation among NSTEMI patients. Despite greater myocardial necrosis in the STEMI group,
results of this pilot-study indicated the prolonged perforin-mediated inflammatory response in patients with NSTEMI.
This perforin down-regulation that follows the coronary interventional reperfusion in STEMI emphasized the possible
anti-inflammatory role of primary PCI among patients with acute myocardial infarction. Given that the issue of routine
primary PCI in NSTEMI is nowadays highly topical, the results we expect in the wake of this pilot study could demon-
strate a significant impact on clinical practice. Further research is needed to confirm these results, compare the perfo-
rin-mediated activity to other inflammatory mediators in acute coronary events and to examine their impact on the
long-term outcome.
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Introduction
Despite considerable progress in treatment over the
past decade, cardiovascular diseases (CVD) are still the
leading causes of premature death in Europe1. Among all
CVD, the coronary artery disease is still associated with
significant morbidity and mortality and in Croatia re-
mains the leading cause of death2. The well known patho-
physiology of myocardial infarction is based on advanced
atherosclerosis with superimposed thrombosis, both in-
fluenced by various cardiovascular risk factors.
Among them, the inflammatory background of chronic
atherosclerosis development and the occurrence of acute
myocardial infarction, as its unexpected complication is
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becoming increasingly interesting area of research. Low
density lipoproteins accumulated in intima activate the
endothelium to express leukocyte adhesion molecules
and chemokines (IL-8, macrophage chemoattractant pro-
tein 1) that promote their pro-inflammatory Th1 activa-
tion and recruitment of immune effectors in the vessel
wall3. Only lately the important impacts of immune ef-
fectors and inflammation on acute coronary atheroscle-
rotic plaque rupture have been investigated. T cells kill
vascular smooth muscle cells with the efficacy of lympho-
kine activated killer4 using cellular cytotoxic mediators5
and contribute to plaque destabilisation. The cellular
stress proteins including heat shock proteins released
from the ruptured plaque and particularly from the in-
farcted myocardium can induce a further strong proin-
flammatory response6,7 by supporting interleukin (IL)-1,
IL-12, IL-18, interferon gamma (IFN-g) and tumor ne-
crosis factor alpha (TNF-a) production and secretion in
patients with acute coronary syndrome8,9. These inflam-
matory cytokines in the early period after acute myocar-
dial infarction enhance not only local, but also general
cell mediated immune response with vascular and myo-
cardial damaging effects in terms of left ventricular per-
formance and patient outcome10,11. There are investiga-
tions showing that the level of inflammatory reactions
gradually regresses spontaneously during the first month
after the acute incident and some of the therapeutic pro-
cedures, such as physical training, may significantly sti-
mulate their fall10. The influence of therapeutic procedures
during the early myocardial phase on the subsequent in-
flammatory response, especially the role of the primary
percutaneous coronary intervention (PCI) is one of the
most important opened issues.
In addition to further investigation on cytokines, it is
also necessary to explore a variety of other potentially
harmful mediators that might be involved in the cardio-
vascular inflammatory reactions. Certainly, one of them is
perforin, a quick-action cytotoxic mediator saved together
with pro-apoptotic molecules in the cytoplasmic granules
of the immune effector-cells (T lymphocytes, NK and
NKT cells)12–14. After stimulated degranulation, perforin
is released into the immunologic synapse and clings to
the membrane of target cells creating a cylindrical pore.
That way perforin induces target cell necrosis or apoptosis
by allowing the access of pro-apoptotic molecules12,13,15.
Although the precise mechanisms of perforin-mediated
cell death are not completely understood, it is considered
as the important inflammatory molecule participating in
cell mediated killing during the immunological tissue
damage16. Perforin positive cells were detected in myo-
cardial tissue during Trypanosoma cruzi infection17 and
viral myocarditis18,19, but the role of this important cyto-
toxic mediator has been very poorly explored in athero-
sclerotic cardiovascular diseases19. There is insufficient
knowledge and understanding about the involvement of
perforin in the immune reactions with myocardial infarc-
tion during a period of early medical rehabilitation com-
prising four weeks after the acute myocardial infarction.
The aim of this pilot study was to investigate the changes
in perforin protein expression in peripheral blood lym-
phocytes during the early period after acute myocardial
infarction, as a function of ongoing inflammation in
women with STEMI which underwent PCI and in women
with NSTEMI which were conservatively treated.
Materials and Methods
Patients
In this pilot study, we enrolled ten patients in the
early period after acute myocardial infarction, during
their rehabilitation program at the Clinic for cardiovas-
cular diseases diagnosis, prevention and rehabilitation of
the Hospital Thalassotherapia Opatija in Opatija, Croa-
tia. Five women of age 65 (58.25, 73.75) years [median
(25th, 75th percentiles)] were with recent ST-segment ele-
vation acute myocardial infarction (STEMI) that has been
treated by the primary PCI, while another five women of
age 70 years (62.25, 75.75), had the acute myocardial in-
farction without ST-segment elevation (NSTEMI) and
have been conservatively treated. We also included a con-
trol group of five age matched healthy women [57 years
(56, 70)]. The exclusion criteria were: the presence of un-
controlled hypertension, heart failure, uncontrolled ar-
rhythmias, uncontrolled metabolic disease, significant
peripheral vascular disease, active infectious or other in-
flammatory diseases, childbearing age and chronological
age above 80 years.
Patient management
All patients received the routine medical therapy dur-
ing the study and were included in the education and
counselling program in accordance to the European guide-
lines on the cardiovascular prevention and rehabilita-
tion1. There were no differences between groups in the
frequency of standard drug therapy use: beta-blocking
agents (carvedilol 2 x 6.5 mg), ACE-inhibitors (ramipril
5 mg), statin (atorvastatin 10 mg), antiplatelet agents
(acetil salycilyc acid 100 mg and clopidogrel 75 mg in pa-
tients with PCI).
Clinical and laboratory parameters
Blood pressure was measured by indirect method.
Anthropometric parameters that included the body mass
index and the percentage of body fat calculated from skin
folds. The standard haematological and biochemical ana-
lyzes were performed in every patient using XS-1000i,
Sysmex, Kobe, Japan haematology analyser or Dimen-
sion Xpand, Siemens Healthcare Diagnostics, Newark,
Germany, respectively. Concentration of troponin I value
was obtained from patients’ medical documentation (dis-
charge summaries) of the Emergency department in
Rijeka University Hospital Center.
Immunological methods
Isolation of mononuclear cells from peripheral blood
samples on density gradients, the labelling of surface mar-
kers and intracellular protein perforin by immunofluore-
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scent method and analysis by flow cytometer (FACSCa-
libur Becton Dickinson) and Cell Quest software (Becton
Dickinson) were applied according to the international
standardised procedures at the Department of physiol-
ogy and immunology, School of Medicine, Rijeka, Croa-
tia20–24.
Statistical analysis
Statistical analysis was performed in Statistica 8.0
(StatSoft, Inc., Tulsa, OK, USA) using non-parametric
Kruskal–Wallis. Mann-Whitney U test was used to estab-
lish among which groups the difference existed with the
level of significance adjusted to the number of mutual
comparisons. Data are presented as median values and
as 25%–75% (25th percentile – 75th percentile).
Results
Clinical and laboratory characteristic
Clinical and laboratory characteristics were assessed
on the day 7 from the onset of myocardial infarction, ex-
cept the values of troponin I which were measured at the
time of clinical presentation (day 1). The values are
shown in the Figure 1. Concentration of troponin I in the
plasma of STEMI patients was significantly higher then in
NSTEMI patients and both groups of patients have high-
er troponin I concentrations when compared to healthy
control. Additionally, accelerated erythrocyte sedimenta-
tion rate (ESR), absolute leukocyte number, body mass
index (BMI) and percentage of body fat were found in
both patients groups compared to healthy population, al-
though the patient groups did not differ between them-
selves. Absolute erythrocyte number, haemoglobin and
haematocrit in women with myocardial infarction were
statistically significantly lower than in the healthy women.
Systolic and diastolic blood pressure did not basically
change between groups investigated.
Perforin expression
In the shown sample the frequency of perforin expres-
sing lymphocytes in healthy women was 23.4% in respect
to the isotype control. It did not significantly differ from
patients with STEMI on day 7 and 28 (20.4% or 28.57%,
respectively), although it was higher then in STEMI pa-
tients on day 14 and 21. In patients with NSTEMI, the























































































































































































































































































































Fig. 1. Mutual comparisons of the laboratory parameters of women with myocardial infarction with ST segment elevation (STEMI),
woman without ST segment elevation (NSTEMI) and healthy examinees. Five experiments were performed. Levels of statistical signifi-
cance are *p=0.01, **p=0.001, ***p=0.0001.
frequency of perforin expressing lymphocytes was ap-
proximately two, six or three times higher than in STEMI
patients on day 7, 14 and 21. Perforin expression become
basically the same on day 28 in both groups of patients
and did not significantly differ from the healthy examinees.
Results are shown on the Figure 2.
Discussion and Conclusion
A pleiotropic pro-inflammatory imbalance that occurs
in patients with acute myocardial infarction leads to the
consolidation of cell mediated immune response25. It is
still ongoing process in our patients with STEMI and
NSTEMI at the beginning of rehabilitation period as it is
followed by the accustomed parameters such as absolute
number of leukocytes in peripheral blood and accelerated
erythrocyte sedimentation rate26. The chronic inflamma-
tion is confirmed by significantly lower absolute erythro-
cyte number, haemoglobin concentration and haemato-
crit that were again found in both groups of patients with
myocardial infarction when compared to healthy exa-
minees (Figure 1), although these values do not meet the
criteria for anaemia given by World Health Organisation,
National kidney foundation or US National Health and
Nutrition Examination Survay27,28. However, the analy-
sis of perforin expression confirmed (showed) the differ-
ences in the pathogenesis of NSTEMI and STEMI29. The
frequency of perforin expressing lymphocytes, as the
more precise inflammatory and activation lymphocyte
marker revealed stronger inflammatory reaction in pa-
tients with the NSTEMI than in the patients with the
STEMI on day 7 after MI in spite of initially significantly
lower myocardial tissue necrosis, measured by troponin I
concentrations in the plasma. The finding of elevated
perforin-positive lymphocytes on the day 7 after myocar-
dial infarction among conservatively treated NSTEMI
patients was not beyond our expectation, but the persis-
tence of few times higher percentages of perforin ex-
pressing lymphocytes in NSTEMI patients in compari-
A. Ru`i} et al.: Perforin Expression after Myocardial Infarction, Coll. Antropol. 35 (2011) 1: 161–166
164
Fig. 2. A sample of flow cytomerty analysis of perforin positive peripheral blood lymphocytes in healthy examinees (A), patients with non
ST-elevation (B) and patients with ST-elevation myocardial infarction (C) at indicated time points. Solid histogram curves show indi-
rect labeling with Gd9 anti-perforin mb and goat anti-mouse FITC, whereas dashed histogram curves show labeling with irrelevant
isotype matched mouse IgG1.
son to patients with STEMI till the day 28 certainly was.
It is likely that, beside ischemic tissue injury at the culprit
vessel and at the site of myocardial infarction, streng-
then cellular immune reaction particularly in patients
with NSTEMI could additionally damage remote vascu-
lar tissue at systemic levels. This hypothesis is in accor-
dance with the previous observation of intra-plaque ex-
pansion of auto-antigen specific CD4+CD28– T cell clones
in patients with ACS30. These lymphokine-activated cells
functionally resemble NK cells31 and they are very effec-
tive in establishing immunologic synapse with vascular
smooth muscle cells and in triggering cell death in vitro32.
These cells produce perforin30 which is involved in erup-
tion of plaque with superimposed thrombosis and occur-
rence of MI32.
Cytotoxicity mediated by perforin is the major effec-
tor pathway used by cytotoxic cells33. Perforin is poten-
tially dangerous cytotoxic mediator which induces short
term necrotic cell death34,35 by flux and equilibration of
ionic gradients in target cells, similarly as final complex
of C5-C9 components34, sometimes for less than 2 hours36.
Additionally, perforin enables un-scheduled target cell
apoptosis by allowing the influx of pro-apoptotic mole-
cules through the perforin pore37 or perforin acts as a
co-factor for the induction of apoptosis in the sublytic
concentrations by unknown mechanism38. In both cases,
the activation of a family of death-inducing proteases
called caspases occur39. Since perforin could drive target
cells apoptosis, it could also activate the anti-inflamma-
tory program mediated by apoptotic cells40. However the
difference between perforin expression in patients with
NSTEMI and STEMI is difficult to explain according to
the data available in the scientific publications. Over-
weight and increased percentage of body fat are gener-
ally associated with pro-inflammatory reaction41, but
they are unlikely to be the reasons for increased inflam-
matory response in patients with NSTEMI since the sig-
nificant difference in BMI and the percentage of body fat
were not observed between patients with STEMI and
NSTEMI groups. According to the satisfactory regula-
tion of the blood glucose concentrations and arterial
blood pressure it is hard to imagine that they are the rea-
sons for the current worsening of endothelial dysfunc-
tion which could activated lymphocytes30 and increased
percentage of perforin expressing cells. According to the
experimental model of myocardial infarction, increased
early postinfarction perforin expression could be associ-
ated with a marked endothelial dysfunction that occurs
seven days after coronary artery ligation42. It suits well
with significant reduction of the frequency of perforin
positive lymphocytes in primary PCI treated STEMI pa-
tients which is prominent on day 14 after the acute coro-
nary event. It seems that stent re-vascularisation method
has the pivotal role in quick quenching the inflammation
within the meaning of perforin, beside its clinical bene-
fits for the patients with myocardial infarction43, since
PCI has been the major difference between the examined
groups of patients in our pilot study. PCI with stent im-
plantation successfully opens culprit coronary lesion and
suspends ischemic myocardial process44 in STEMI pa-
tients with significant myocardial tissue necrosis.
No matter what the cause and mechanism(s) of the
decrease of perforin expression were in STEMI patients
on the day 14, this finding brings the question of additio-
nal benefits that all patients with acute myocardial in-
farction could have from the early percutaneous inter-
ventions. Our preliminary results contribute to the great
attention that is nowadays paid to this topic and support
the need to introduce routine primary PCI in the treat-
ment of NSTEMI patients45. However, toward the better
understanding of the role of perforin in myocardial in-
farction further research is needed to confirm our re-
sults, to broad the investigation to the earliest time of its
clinical presentation and regulation or even to conduct a
study that would prospectively interface the perforin ex-
pression and acute coronary event occurrence, the post-
myocardial clinical course and the long-term outcome.
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EKSPRESIJA PERFORINA NAKON AKUTNOG INFARKTA MIOKARDA – PILOT-STUDIJA
S A @ E T A K
Perforin je va`an medijator upalnih reakcija, brzodjeluju}i citotoksi~ni posrednik pohranjen u citoplazmatskim gra-
nulama izvr{nih stanica imuniteta (T limfocita, NK stanica i NKT stanica) koji posreduje u formiranju smrtonosnog
signala spram zara`enih ili druk~ije zna~ajno promijenjenih stanica. Perforin-pozitivne stanice otkrivene su u miokard-
nom tkivu pri kardiovaskularnim bolestima kao {to su infekcija Trypanosomom cruzi ili virusni miokarditis, dok je
njihova uloga u drugim upalnim bolestima, kao npr. u aterosklerozi i akutnom koronarnom sindromu, gotovo potpuno
neistra`ena. Cilj ovog istra`ivanja stoga je bio ispitati prisutnost perforina u limfocitima periferne krvi bolesnika tije-
kom ranog razdoblja nakon akutnog infarkta miokarda. Analizirali smo tri skupine: bolesnice oboljele od akuktnog in-
farkta miokarda s elevacijom ST-segmenta (STEMI) koje su bile lije~ene primarnom perkutanom intervencijom (PCI),
konzervativno lije~ene bolesnice s akutnim infarktom miokarda bez elevacije ST-segmenta (NSTEMI) i kontrolnu sku-
pinu dobrovoljki. Skupine STEMI i NSTEMI nisu se razlikovale prema primijenjenoj medikamenoznoj terapiji niti po
razinama rutinskih laboratorijskih nalaza, a samo su razine troponina I bile zna~ajno vi{e u STEMI skupini. Zabilje`ili
smo rano smanjenje perforin-pozitivnih limfocita u STEMI-bolesnica koje je bilo u kontrastu s njihovim perzistiranjem
unutar NSTEMI skupine. Usprkos ve}oj nekrozi miokarda u STEMI grupi bolesnica, rezultati ove pilot studije ukazali
su na sna`nu nishodnu regulaciju peroforina tijekom drugog tjedna nakon infarkta miokarda u ovoj grupi, istakli pro-
duljeni upalni odgovor posredovan perforinom u NSTEMI bolesnica, te time skrenuli pa`nju na mogu}u protuupalnu
ulogu PCI u akutnom infarktu miokarda. Obzirom da je pitanje primarne PCI u rutinskom zbrinjavanju NSTEMI
bolesnika vrlo akutalno, budu}i rezultati koje na tragu ove pilot studije o~ekujemo, mogli bi iskazati zna~ajan utjecaj na
klini~ku praksu. Potrebna su daljnja istra`ivanja za potvrdu iznesenih rezultata, kao i usporedba perforinom-posredo-
vane upalne aktivnosti s drugim upalnim medijatorima u ranoj fazi nakon akutnog infarkta miokarda, te procjena ut-
jecaja postinfarktne perforinske aktivnosti na dugoro~ni klini~ki ishod.
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